Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Argos Therapeutics Inc.
DescriptionSecond-generation RNA-loaded autologous dendritic cell immunotherapy
Molecular Target Not applicable
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationRenal cancer
Indication DetailsFirst-line treatment of advanced renal cell carcinoma (RCC); Treat metastatic renal cell carcinoma (RCC)
Regulatory Designation U.S. - Fast Track (Treat metastatic renal cell carcinoma (RCC));
U.S. - Special Protocol Assessment (Treat metastatic renal cell carcinoma (RCC))
Partner Chongqing Lummy Pharmaceutical Co. Ltd.; Green Cross Corp.; Pharmstandard OJSC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today